Explore By Subject Area   
Return Home
Register Here Menu

Immuno-Oncology 360°

Date: Mar 24, 2025 - Mar 26, 2025

Location: Boston, MA

Day One: Monday, March 24, 2025
Showing Events in 1 Track from 07:30am to 08:15am
Morning Remarks
7:30AM - 8:05AM
Registration
8:05AM - 8:15AM
IO360º Opening Remarks
Speakers:
James Gulley, MD, PhD, FACP, Co-Director, Center for Immuno-Oncology, CCR & Clinical Director, National Cancer Institute, NIH
Axel Hoos, MD, PhD, Former CEO, Scorpion Therapeutics
Showing Events in 1 Track from 08:15am to 08:40am
Opening Keynote
8:15AM - 8:40AM
Opening Keynote: Evolution and Future Directions in Cell Therapy - Overcoming Challenges and Pioneering Innovations
Keynote Speaker:
Crystal Mackall, MD, FAAP, FAACR, Ernest and Amelia Gallo Family Professor and Professor of Pediatrics and Medicine; Founding Director, Stanford Center for Cancer Cell Therapy; Director, Parker Institute for Cancer Immunotherapy @ Stanford; Associate Director, Stanford Cancer Institute, Stanford University
Showing Events in 1 Track from 08:40am to 09:20am
Morning Session
8:40AM - 9:00AM
Fundamental Biology Talk: Neoantigen Vaccines for Pancreatic Cancer
Speaker:
William Hawkins, MD, Deputy Director, Hollings Cancer Center; Vice Chair of Clinical Affairs, Department of Surgery, AR Folk Professor of Surgery, MUSC Hollings Cancer Center
9:00AM - 9:20AM
Designing Best in Class ADCs for IO: Principles and Strategies
Speaker:
Deepa Pakianathan, PhD, Managing Partner and CEO/Co-Founder, Delphi Ventures / Stealth Oncology Company
Showing Events in 1 Track from 09:20am to 10:00am
Grand Opening of the IO360° Networking Café
9:20AM - 10:00AM
Grand Opening of the IO360° Networking Café
Showing Events in 1 Track from 10:00am to 11:15am
New Technologies in Transformational Biology Plenary
Track Chair:
Axel Hoos, MD, PhD, Former CEO, Scorpion Therapeutics
10:00AM - 10:20AM
Immunological Effects of Radiopharmaceuticals
Speaker:
Dushen Chetty, PhD, VP, Global Program Head, Oncology, Novartis
10:20AM - 11:05AM
Navigating Project Optimus: Balancing Innovation and Practicality in IO Dose Selection
Moderator:
Gideon Blumenthal, MD, VP, Clinical Development Oncology, Merck Research Labs
Panelists:
Greg Goldmacher, MD, PhD, MBA, Associate VP, Clinical Research; Head, Clinical Imaging & Pathology, Merck Research Laboratories
Wim Vos, PhD, CEO, Radiomics
11:05AM - 11:15AM
10 Min Health Break
Showing Events in 2 Tracks from 11:15am to 12:30pm
Track 1: IO Novel Technologies Showcase A
Track Chair:
David Leung, MD, PhD, Head of Imaging, Daiichi Sankyo
11:15AM - 12:30PM
Track 1: IO Novel Technologies Showcase A
Track Chair:
David Leung, MD, PhD, Head of Imaging, Daiichi Sankyo
Participating Companies:
Track 2: IO Novel Technologies Showcase B
11:15AM - 12:30PM
Track 2: IO Novel Technologies Showcase B
Participating Companies:
Showing Events in 2 Tracks from 12:30pm to 01:45pm
Lunch & One-on-One Meetings Begin
12:30PM - 1:45PM
Lunch & One-on-One Meetings Begin
Women Leaders in IO Luncheon & Panel Discussion - Pre-Registration with Ticket Required
12:30PM - 1:45PM
Women Leaders in IO Luncheon & Panel Discussion - Pre-Registration with Ticket Required
Moderator:
Christine Ward, PhD, VP, Head of Translational Medicine - Therapeutics & Oncology Development, Moderna
Panelists:
Rachel Humphrey, MD, President and Founding CEO, Normunity
Ashley Lakner, Head, Oncology Discovery - pRED Oncology, Roche
Caroline Loew, PhD, CEO, Mural Oncology
Showing Events in 2 Tracks from 01:45pm to 03:15pm
Track 1: New Tech in Transformational Biology (continued)
Track Chair:
James Gulley, MD, PhD, FACP, Co-Director, Center for Immuno-Oncology, CCR & Clinical Director, National Cancer Institute, NIH
1:45PM - 2:05PM
ADCs and IO Combinations
Speaker:
Raluca Verona, PhD, Head, Oncology Precision Medicine Group, AbbVie
2:20PM - 2:40PM
Progress on CD22 TCR-T
Speaker:
Kazusa Ishii, MD, MPH, Head Hematologic Malignancies Cellular Therapy Group, Center for Immuno-Oncology, National Cancer Institute
2:55PM - 3:15PM
Combatting Fatigue of Engineered T-Cells
Track 2: Oncology Clinical Operations
Track Chair:
Andy Lee, SVP, Head of Global Clinical Trial Operations, Merck & Co., Inc.
1:45PM - 2:25PM
Navigating the Shifting Landscape of Trial Placement and Site Selection for Global Oncology Research
Moderator:
Andy Lee, SVP, Head of Global Clinical Trial Operations, Merck & Co., Inc.
Panelist:
Sarah A. White, MPH, Executive Director, Multi-Regional Clinical Trials Center, Brigham and Women’s Hospital and Harvard (MRCT Center)
2:25PM - 3:05PM
Strategies for Overcoming Drug and Comparator Sourcing Challenges in Oncology Trials
Moderator:
Marta Arias-Salgado, Head, Global Clinical Supply, Merck Research Labs
Panelists:
Luisa Freitas dos Santos, PhD, Head, Clinical Supply, GSK
Michael Ku, PharmD, MBA, Head, Global Clinical Supply, Pfizer
3:05PM - 3:15PM
Central Review of Immuno-Oncology Efficacy Data: Current Status and Future Developments
Speaker:
Richard Walovitch, PhD, CSO, Voiant
Showing Events in 1 Track from 03:15pm to 03:55pm
Afternoon Networking Break
3:15PM - 3:55PM
Afternoon Networking Break
Showing Events in 2 Tracks from 03:55pm to 05:55pm
Track 1: Breakthroughs in Translational Science, Imaging and Biomarkers (Pt 1)
3:55PM - 4:15PM
Landscape Talk: Intersection of ADCs and Cancer Immunotherapy
Speaker:
Jonathan Rosenberg, MD, Chief, Genitourinary Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center
4:15PM - 4:30PM
Harnessing Spatial Biology for Enhanced Cancer Immunotherapy Treatment
Speaker:
B. Dusty Majumdar, PhD, CEO, PredxBio
4:30PM - 5:15PM
Panel: Advancing Biomarker Discovery and Patient Selection in Immuno-Oncology through Innovative Technologies
Moderator:
Anne-Marie Martin, PhD, SVP & Global Head, Precision Medicine, R&D, GSK
Panelists:
Gregory Frank, PhD, Global Scientific Partnering Strategy, Immuno-Oncology, GE HealthCare
Catherine Hines, PhD, Executive Director and Head, Clinical Imaging, GSK
Jayant Narang, MD, Sr Medical Director, Clinical Oncology Imaging Lead, Preclinical and Translational Sciences, Takeda Pharmaceuticals
5:15PM - 5:30PM
Leveraging AI Models for Pathology Image Analysis to Advance Drug Development
Speaker:
Siraj Ali, MD, PhD, Global VP of Translational Medicine, Lunit
5:30PM - 5:50PM
Targeting the B7-H7 Axis for Cancer Immunotherapy
Speaker:
Tatiana Novobrantseva, PhD, CSO, NextPoint Therapeutics
Track 2: Oncology Clinical Operations (continued)
Track Chair:
Andy Lee, SVP, Head of Global Clinical Trial Operations, Merck & Co., Inc.
3:55PM - 4:35PM
Overcoming Operational and Regulatory Challenges in Utilizing Prognostic Markers for Oncology Research
Speakers:
Andy Lee, SVP, Head of Global Clinical Trial Operations, Merck & Co., Inc.
John Simmons, PhD, Global VP, Biopharma Partnerships, Natera
4:35PM - 5:15PM
Strategies for Equitable Enrollment in Oncology and Cancer Immunotherapy Trials
Panelists:
Brittany Gerald-Lewis, Associate Director, Clinical Trial Health Equity, Moderna
Julie Martin, MSc, MBA, CEO & Co-Owner, Scimega Research
Jeanne Regnante, Strategic Health Equity Advisor & Founder, Tigerlily Foundation & Patient 3i, LLC
5:15PM - 5:55PM
Enhancing Integrity in Oncology Trials: Strategies for Endpoint Management, Data Oversight, and Ethical Decision-Making
Moderator:
Christine Gause, PhD, VP, Late Development Statistics, Merck
Showing Events in 1 Track from 05:55pm to 07:00pm
11th Annual Networking Reception & One-on-One Meetings
5:55PM - 7:00PM
11th Annual Networking Reception & One-on-One Meetings
Showing Events in 1 Track from 07:30am to 08:15am
Morning Remarks
7:30AM - 8:05AM
Registration
8:05AM - 8:15AM
IO360º Opening Remarks
Speakers:
James Gulley, MD, PhD, FACP, Co-Director, Center for Immuno-Oncology, CCR & Clinical Director, National Cancer Institute, NIH
Axel Hoos, MD, PhD, Former CEO, Scorpion Therapeutics
Showing Events in 1 Track from 08:15am to 08:40am
Opening Keynote
8:15AM - 8:40AM
Opening Keynote: Evolution and Future Directions in Cell Therapy - Overcoming Challenges and Pioneering Innovations
Keynote Speaker:
Crystal Mackall, MD, FAAP, FAACR, Ernest and Amelia Gallo Family Professor and Professor of Pediatrics and Medicine; Founding Director, Stanford Center for Cancer Cell Therapy; Director, Parker Institute for Cancer Immunotherapy @ Stanford; Associate Director, Stanford Cancer Institute, Stanford University
Showing Events in 1 Track from 08:40am to 09:20am
Morning Session
8:40AM - 9:00AM
Fundamental Biology Talk: Neoantigen Vaccines for Pancreatic Cancer
Speaker:
William Hawkins, MD, Deputy Director, Hollings Cancer Center; Vice Chair of Clinical Affairs, Department of Surgery, AR Folk Professor of Surgery, MUSC Hollings Cancer Center
9:00AM - 9:20AM
Designing Best in Class ADCs for IO: Principles and Strategies
Speaker:
Deepa Pakianathan, PhD, Managing Partner and CEO/Co-Founder, Delphi Ventures / Stealth Oncology Company
Showing Events in 1 Track from 09:20am to 10:00am
Grand Opening of the IO360° Networking Café
9:20AM - 10:00AM
Grand Opening of the IO360° Networking Café
Showing Events in 1 Track from 10:00am to 11:15am
New Technologies in Transformational Biology Plenary
Track Chair:
Axel Hoos, MD, PhD, Former CEO, Scorpion Therapeutics
10:00AM - 10:20AM
Immunological Effects of Radiopharmaceuticals
Speaker:
Dushen Chetty, PhD, VP, Global Program Head, Oncology, Novartis
10:20AM - 11:05AM
Navigating Project Optimus: Balancing Innovation and Practicality in IO Dose Selection
Moderator:
Gideon Blumenthal, MD, VP, Clinical Development Oncology, Merck Research Labs
Panelists:
Greg Goldmacher, MD, PhD, MBA, Associate VP, Clinical Research; Head, Clinical Imaging & Pathology, Merck Research Laboratories
Wim Vos, PhD, CEO, Radiomics
11:05AM - 11:15AM
10 Min Health Break
Showing Events in 2 Tracks from 11:15am to 12:30pm
Track 1: IO Novel Technologies Showcase A
Track Chair:
David Leung, MD, PhD, Head of Imaging, Daiichi Sankyo
11:15AM - 12:30PM
Track 1: IO Novel Technologies Showcase A
Track Chair:
David Leung, MD, PhD, Head of Imaging, Daiichi Sankyo
Participating Companies:
Track 2: IO Novel Technologies Showcase B
11:15AM - 12:30PM
Track 2: IO Novel Technologies Showcase B
Participating Companies:
Showing Events in 2 Tracks from 12:30pm to 01:45pm
Lunch & One-on-One Meetings Begin
12:30PM - 1:45PM
Lunch & One-on-One Meetings Begin
Women Leaders in IO Luncheon & Panel Discussion - Pre-Registration with Ticket Required
12:30PM - 1:45PM
Women Leaders in IO Luncheon & Panel Discussion - Pre-Registration with Ticket Required
Moderator:
Christine Ward, PhD, VP, Head of Translational Medicine - Therapeutics & Oncology Development, Moderna
Panelists:
Rachel Humphrey, MD, President and Founding CEO, Normunity
Ashley Lakner, Head, Oncology Discovery - pRED Oncology, Roche
Caroline Loew, PhD, CEO, Mural Oncology
Showing Events in 2 Tracks from 01:45pm to 03:15pm
Track 1: New Tech in Transformational Biology (continued)
Track Chair:
James Gulley, MD, PhD, FACP, Co-Director, Center for Immuno-Oncology, CCR & Clinical Director, National Cancer Institute, NIH
1:45PM - 2:05PM
ADCs and IO Combinations
Speaker:
Raluca Verona, PhD, Head, Oncology Precision Medicine Group, AbbVie
2:20PM - 2:40PM
Progress on CD22 TCR-T
Speaker:
Kazusa Ishii, MD, MPH, Head Hematologic Malignancies Cellular Therapy Group, Center for Immuno-Oncology, National Cancer Institute
2:55PM - 3:15PM
Combatting Fatigue of Engineered T-Cells
Track 2: Oncology Clinical Operations
Track Chair:
Andy Lee, SVP, Head of Global Clinical Trial Operations, Merck & Co., Inc.
1:45PM - 2:25PM
Navigating the Shifting Landscape of Trial Placement and Site Selection for Global Oncology Research
Moderator:
Andy Lee, SVP, Head of Global Clinical Trial Operations, Merck & Co., Inc.
Panelist:
Sarah A. White, MPH, Executive Director, Multi-Regional Clinical Trials Center, Brigham and Women’s Hospital and Harvard (MRCT Center)
2:25PM - 3:05PM
Strategies for Overcoming Drug and Comparator Sourcing Challenges in Oncology Trials
Moderator:
Marta Arias-Salgado, Head, Global Clinical Supply, Merck Research Labs
Panelists:
Luisa Freitas dos Santos, PhD, Head, Clinical Supply, GSK
Michael Ku, PharmD, MBA, Head, Global Clinical Supply, Pfizer
3:05PM - 3:15PM
Central Review of Immuno-Oncology Efficacy Data: Current Status and Future Developments
Speaker:
Richard Walovitch, PhD, CSO, Voiant
Showing Events in 1 Track from 03:15pm to 03:55pm
Afternoon Networking Break
3:15PM - 3:55PM
Afternoon Networking Break
Showing Events in 2 Tracks from 03:55pm to 05:55pm
Track 1: Breakthroughs in Translational Science, Imaging and Biomarkers (Pt 1)
3:55PM - 4:15PM
Landscape Talk: Intersection of ADCs and Cancer Immunotherapy
Speaker:
Jonathan Rosenberg, MD, Chief, Genitourinary Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center
4:15PM - 4:30PM
Harnessing Spatial Biology for Enhanced Cancer Immunotherapy Treatment
Speaker:
B. Dusty Majumdar, PhD, CEO, PredxBio
4:30PM - 5:15PM
Panel: Advancing Biomarker Discovery and Patient Selection in Immuno-Oncology through Innovative Technologies
Moderator:
Anne-Marie Martin, PhD, SVP & Global Head, Precision Medicine, R&D, GSK
Panelists:
Gregory Frank, PhD, Global Scientific Partnering Strategy, Immuno-Oncology, GE HealthCare
Catherine Hines, PhD, Executive Director and Head, Clinical Imaging, GSK
Jayant Narang, MD, Sr Medical Director, Clinical Oncology Imaging Lead, Preclinical and Translational Sciences, Takeda Pharmaceuticals
5:15PM - 5:30PM
Leveraging AI Models for Pathology Image Analysis to Advance Drug Development
Speaker:
Siraj Ali, MD, PhD, Global VP of Translational Medicine, Lunit
5:30PM - 5:50PM
Targeting the B7-H7 Axis for Cancer Immunotherapy
Speaker:
Tatiana Novobrantseva, PhD, CSO, NextPoint Therapeutics
Track 2: Oncology Clinical Operations (continued)
Track Chair:
Andy Lee, SVP, Head of Global Clinical Trial Operations, Merck & Co., Inc.
3:55PM - 4:35PM
Overcoming Operational and Regulatory Challenges in Utilizing Prognostic Markers for Oncology Research
Speakers:
Andy Lee, SVP, Head of Global Clinical Trial Operations, Merck & Co., Inc.
John Simmons, PhD, Global VP, Biopharma Partnerships, Natera
4:35PM - 5:15PM
Strategies for Equitable Enrollment in Oncology and Cancer Immunotherapy Trials
Panelists:
Brittany Gerald-Lewis, Associate Director, Clinical Trial Health Equity, Moderna
Julie Martin, MSc, MBA, CEO & Co-Owner, Scimega Research
Jeanne Regnante, Strategic Health Equity Advisor & Founder, Tigerlily Foundation & Patient 3i, LLC
5:15PM - 5:55PM
Enhancing Integrity in Oncology Trials: Strategies for Endpoint Management, Data Oversight, and Ethical Decision-Making
Moderator:
Christine Gause, PhD, VP, Late Development Statistics, Merck
Showing Events in 1 Track from 05:55pm to 07:00pm
11th Annual Networking Reception & One-on-One Meetings
5:55PM - 7:00PM
11th Annual Networking Reception & One-on-One Meetings
Previous
Day One
Monday, March 24, 2025

Subscribe for More Information

Please provide your contact information and select areas of interest to receive updates.